# QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

> **NCT04052061** · PHASE1 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Large-cell Lymphoma
- Lymphoma, B-Cell
- Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 t-haNK

## Key facts

- **NCT ID:** NCT04052061
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-16
- **Primary completion:** 2021-09-18
- **Final completion:** 2022-08-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial not initiated
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04052061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04052061, "QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04052061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*